Interleukin-6 Receptor Inhibition in Covid-19 — Cooling the Inflammatory Soup
Viruses cannot replicate by themselves. Instead, they rely on the host for almost all their replicative functions. Similarly, many viruses are unable to cause damage without the host immune system. Because of this, two strategies can often ameliorate disease — antivirals, which block replication, an...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2021-04, Vol.384 (16), p.1564-1565 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1565 |
|---|---|
| container_issue | 16 |
| container_start_page | 1564 |
| container_title | The New England journal of medicine |
| container_volume | 384 |
| creator | Rubin, Eric J Longo, Dan L Baden, Lindsey R |
| description | Viruses cannot replicate by themselves. Instead, they rely on the host for almost all their replicative functions. Similarly, many viruses are unable to cause damage without the host immune system. Because of this, two strategies can often ameliorate disease — antivirals, which block replication, and antiinflammatories, which can limit the damage induced by infection. In the lung, this latter strategy is exemplified by the treatment of
Pneumocystis jiroveci
, in which treatment with glucocorticoids reduces the severity of disease and the risk of death.
1,2
However, because blocking inflammatory pathways raises the possibility of diminishing the host response and increasing replication of . . . |
| doi_str_mv | 10.1056/NEJMe2103108 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7944949</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2494294018</sourcerecordid><originalsourceid>FETCH-LOGICAL-c593t-950a374da6c7eafdaf1d39bfbe9d039c39651881665d28d7534cc6c0fdc5098b3</originalsourceid><addsrcrecordid>eNpt0U1LHDEcBvAgFXd9ufVcBurBQ0eTyctMLoIsW12xFXw5h0yScbOdSdZkRtibH6Kf0E_SyKpsS3MJIb885M8DwGcEjxGk7OTn9PKHKRDECFZbYIwoxjkhkH0CYwiLKiclxyOwG-MCpoUI3wEjjFnijIzB9cz1JrRm-GVdzrIbo8yy9yGbubmtbW-9y6zLJv7J6hzx7OX5dzr41rqHrJ-bxJpWdp1MT1bZrR-W-2C7kW00B2_7Hrj_Pr2bXORX1-ezydlVrijHfc4plLgkWjJVGtlo2SCNed3UhmuIucKcUVRViDGqi0qXFBOlmIKNVhTyqsZ74HSduxzqzmhlXB9kK5bBdjKshJdW_H3j7Fw8-CdRckI44Sng6C0g-MfBxF50NirTttIZP0RRJFVwAlGV6Nd_6MIPwaXxREERK0pI0Gvgt7VSwccYTPPxGQTFa1Nis6nEv2wO8IHfq0ngcA26LgpnFt3_c_4A1L-Zng</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2516270419</pqid></control><display><type>article</type><title>Interleukin-6 Receptor Inhibition in Covid-19 — Cooling the Inflammatory Soup</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Rubin, Eric J ; Longo, Dan L ; Baden, Lindsey R</creator><creatorcontrib>Rubin, Eric J ; Longo, Dan L ; Baden, Lindsey R</creatorcontrib><description>Viruses cannot replicate by themselves. Instead, they rely on the host for almost all their replicative functions. Similarly, many viruses are unable to cause damage without the host immune system. Because of this, two strategies can often ameliorate disease — antivirals, which block replication, and antiinflammatories, which can limit the damage induced by infection. In the lung, this latter strategy is exemplified by the treatment of
Pneumocystis jiroveci
, in which treatment with glucocorticoids reduces the severity of disease and the risk of death.
1,2
However, because blocking inflammatory pathways raises the possibility of diminishing the host response and increasing replication of . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMe2103108</identifier><identifier>PMID: 33631064</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Antiviral agents ; Antiviral drugs ; Coronaviruses ; COVID-19 ; Cytokines ; Glucocorticoids ; Humans ; Immune system ; Infections ; Inflammation ; Interleukin 6 ; Mortality ; Receptors, Interleukin-6 ; Replication ; SARS-CoV-2 ; Severe acute respiratory syndrome coronavirus 2</subject><ispartof>The New England journal of medicine, 2021-04, Vol.384 (16), p.1564-1565</ispartof><rights>Copyright © 2021 Massachusetts Medical Society. All rights reserved.</rights><rights>Copyright © 2021 Massachusetts Medical Society. All rights reserved. 2021 Massachusetts Medical Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c593t-950a374da6c7eafdaf1d39bfbe9d039c39651881665d28d7534cc6c0fdc5098b3</citedby><cites>FETCH-LOGICAL-c593t-950a374da6c7eafdaf1d39bfbe9d039c39651881665d28d7534cc6c0fdc5098b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMe2103108$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2516270419?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,314,778,782,883,2748,2749,26090,27911,27912,52369,54051,64370,64372,64374,72224</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33631064$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rubin, Eric J</creatorcontrib><creatorcontrib>Longo, Dan L</creatorcontrib><creatorcontrib>Baden, Lindsey R</creatorcontrib><title>Interleukin-6 Receptor Inhibition in Covid-19 — Cooling the Inflammatory Soup</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>Viruses cannot replicate by themselves. Instead, they rely on the host for almost all their replicative functions. Similarly, many viruses are unable to cause damage without the host immune system. Because of this, two strategies can often ameliorate disease — antivirals, which block replication, and antiinflammatories, which can limit the damage induced by infection. In the lung, this latter strategy is exemplified by the treatment of
Pneumocystis jiroveci
, in which treatment with glucocorticoids reduces the severity of disease and the risk of death.
1,2
However, because blocking inflammatory pathways raises the possibility of diminishing the host response and increasing replication of . . .</description><subject>Antiviral agents</subject><subject>Antiviral drugs</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Cytokines</subject><subject>Glucocorticoids</subject><subject>Humans</subject><subject>Immune system</subject><subject>Infections</subject><subject>Inflammation</subject><subject>Interleukin 6</subject><subject>Mortality</subject><subject>Receptors, Interleukin-6</subject><subject>Replication</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpt0U1LHDEcBvAgFXd9ufVcBurBQ0eTyctMLoIsW12xFXw5h0yScbOdSdZkRtibH6Kf0E_SyKpsS3MJIb885M8DwGcEjxGk7OTn9PKHKRDECFZbYIwoxjkhkH0CYwiLKiclxyOwG-MCpoUI3wEjjFnijIzB9cz1JrRm-GVdzrIbo8yy9yGbubmtbW-9y6zLJv7J6hzx7OX5dzr41rqHrJ-bxJpWdp1MT1bZrR-W-2C7kW00B2_7Hrj_Pr2bXORX1-ezydlVrijHfc4plLgkWjJVGtlo2SCNed3UhmuIucKcUVRViDGqi0qXFBOlmIKNVhTyqsZ74HSduxzqzmhlXB9kK5bBdjKshJdW_H3j7Fw8-CdRckI44Sng6C0g-MfBxF50NirTttIZP0RRJFVwAlGV6Nd_6MIPwaXxREERK0pI0Gvgt7VSwccYTPPxGQTFa1Nis6nEv2wO8IHfq0ngcA26LgpnFt3_c_4A1L-Zng</recordid><startdate>20210422</startdate><enddate>20210422</enddate><creator>Rubin, Eric J</creator><creator>Longo, Dan L</creator><creator>Baden, Lindsey R</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20210422</creationdate><title>Interleukin-6 Receptor Inhibition in Covid-19 — Cooling the Inflammatory Soup</title><author>Rubin, Eric J ; Longo, Dan L ; Baden, Lindsey R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c593t-950a374da6c7eafdaf1d39bfbe9d039c39651881665d28d7534cc6c0fdc5098b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antiviral agents</topic><topic>Antiviral drugs</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Cytokines</topic><topic>Glucocorticoids</topic><topic>Humans</topic><topic>Immune system</topic><topic>Infections</topic><topic>Inflammation</topic><topic>Interleukin 6</topic><topic>Mortality</topic><topic>Receptors, Interleukin-6</topic><topic>Replication</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rubin, Eric J</creatorcontrib><creatorcontrib>Longo, Dan L</creatorcontrib><creatorcontrib>Baden, Lindsey R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rubin, Eric J</au><au>Longo, Dan L</au><au>Baden, Lindsey R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Interleukin-6 Receptor Inhibition in Covid-19 — Cooling the Inflammatory Soup</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2021-04-22</date><risdate>2021</risdate><volume>384</volume><issue>16</issue><spage>1564</spage><epage>1565</epage><pages>1564-1565</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>Viruses cannot replicate by themselves. Instead, they rely on the host for almost all their replicative functions. Similarly, many viruses are unable to cause damage without the host immune system. Because of this, two strategies can often ameliorate disease — antivirals, which block replication, and antiinflammatories, which can limit the damage induced by infection. In the lung, this latter strategy is exemplified by the treatment of
Pneumocystis jiroveci
, in which treatment with glucocorticoids reduces the severity of disease and the risk of death.
1,2
However, because blocking inflammatory pathways raises the possibility of diminishing the host response and increasing replication of . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>33631064</pmid><doi>10.1056/NEJMe2103108</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2021-04, Vol.384 (16), p.1564-1565 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7944949 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | Antiviral agents Antiviral drugs Coronaviruses COVID-19 Cytokines Glucocorticoids Humans Immune system Infections Inflammation Interleukin 6 Mortality Receptors, Interleukin-6 Replication SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 |
| title | Interleukin-6 Receptor Inhibition in Covid-19 — Cooling the Inflammatory Soup |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T15%3A09%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Interleukin-6%20Receptor%20Inhibition%20in%20Covid-19%20%E2%80%94%20Cooling%20the%20Inflammatory%20Soup&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Rubin,%20Eric%20J&rft.date=2021-04-22&rft.volume=384&rft.issue=16&rft.spage=1564&rft.epage=1565&rft.pages=1564-1565&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMe2103108&rft_dat=%3Cproquest_pubme%3E2494294018%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2516270419&rft_id=info:pmid/33631064&rfr_iscdi=true |